Barbados and Nigeria sign landmark MOU

In a landmark move, the governments of Barbados and Nigeria have formalized a transformative partnership aimed at bolstering local pharmaceutical production, enhancing regulatory collaboration, and expanding market access across the Caribbean, Latin America, ECOWAS, and the African continent. The agreement, encapsulated in a Memorandum of Understanding (MOU), was signed between Barbados Pharmaceuticals Inc. (BPI) and Nigeria’s Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC). This pact establishes a robust framework for cooperation across four critical areas: industrial capacity and human capital development, market access and shaping, clinical trials collaboration, and regulatory, financing, and policy alignment. The MOU follows extensive high-level discussions, including talks between Barbados’ Senior Minister of Health, Dr. Jerome Walcott, and Nigeria’s Coordinating Minister of Health and Social Welfare, Professor Muhammad Ali Pate. It also builds on ongoing efforts with AMA Medical Manufacturing, a leading Nigerian biopharmaceutical company exploring the establishment of a manufacturing facility in Barbados. Minister Walcott hailed the partnership as a significant stride toward health sovereignty, aligning with Prime Minister Mia Amor Mottley’s vision of a transatlantic pharmaceutical bridge connecting Africa, the Caribbean, and Latin America. Professor Pate underscored Nigeria’s commitment to President Bola Ahmed Tinubu’s Executive Order, which aims to achieve 70% domestic production of essential medicines and medical devices by 2030. Key initiatives under the MOU include the development of a Barbados-Nigeria pharmaceutical skills pathway, reciprocal market access, clinical trials integration, regulatory reliance agreements, and a joint financing pipeline with development finance institutions. The partnership also advances discussions with AMA Medical Manufacturing, potentially creating the first Africa-Caribbean pharmaceutical production corridor. A Joint Steering Committee has been established to oversee immediate implementation.